Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in children.
Natama HM. et al, (2024), The Lancet. Infectious diseases
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial
Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117
Vaccine-induced human monoclonal antibodies to PfRH5 show broadly neutralizing activity against P. falciparum clinical isolates.
Thiam LG. et al, (2024), NPJ vaccines, 9
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5.
Harrison TE. et al, (2024), EMBO Mol Med
Plug and play virus-like particles for the generation of anti-toxin antibodies.
Edge RJ. et al, (2024), Toxicon: X, 23
Synergistic blockade of TIGIT and PD-L1 increases type-1 inflammation and improves parasite control during murine blood-stage Plasmodium yoelii non-lethal infection.
Dookie RS. et al, (2024), Infection and immunity
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5.
Wang LT. et al, (2024), Cell
Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.
King LDW. et al, (2024), Cell reports. Medicine, 5
Structure-guided design of aPlasmodium vivaxDuffy binding protein-based vaccine immunogen
Barber NM. et al, (2024)
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development
Mertens JE. et al, (2024), Vaccine, 42, 3621 - 3629
Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
Barrett JR. et al, (2024), Frontiers in Immunology, 14
PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial
Martinez FJ. et al, (2024), npj Vaccines, 9
The PfRCR complex bridges malaria parasite and erythrocyte during invasion.
Farrell B. et al, (2023), Nature
Human monoclonal antibodies inhibit invasion of transgenic Plasmodium knowlesi expressing Plasmodium vivax Duffy binding protein
Watson QD. et al, (2023), Malaria Journal, 22
A systematic analysis of the human immune response to Plasmodium vivax
Bach FA. et al, (2023), Journal of Clinical Investigation, 133